A longitudinal analysis of PD study characteristics provides a deeper understanding of clinical trials dynamics and demonstrate how research paradigms have been changing across the years.
The objective of this study was to develop and support a process for assessing the comparability of data used in global clinical trials from four individual laboratories, wholly owned by the same central laboratory entity, and that the same tests on the same samples are under statistical control and acceptable limits of variation.
Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research.
An evaluation of the effect of hemolysis, icterus and lipemia on chemistry assays and further assessment of the association between the amount of interfering substances and ordinal values reported by the automated chemistry analyzer as H-, I- and L-indices.
Research in diagnosis, management, and therapy development, as well as development of standardized guidelines for upcoming studies need to be addressed in order to improve the prognosis of DFI patients.
In this webinar, medical experts from Medpace’s Infectious Diseases and Hematology/Oncology teams discuss infectious diseases in the immunocompromised host—with a focus on hematologic malignancies and hematopoietic cell transplantation patients—and the unique challenges for clinical development.
In this presentation, Medpace medical and operational experts discuss the trial design challenges for specific oncology populations and how to overcome them.
Pharmacoeconomic assessment of a drug, medical device, or other healthcare product can take on many forms and occur at multiple points in the development cycle. Cost-effectiveness analysis, a major component of pharmacoeconomic assessment, has traditionally occurred in the later phases of product development—either as a piggy-back to a phase III or pivotal clinical trial, or peri-authorization. Join Medpace experts as they explore the application of pharmacoeconomic assessment throughout all phases of clinical trials as well as in observational studies, including registries and other post-marketing data collection.
Planning and executing a clinical study for an orphan indication presents a unique set of challenges and considerations. In this webinar, Michelle Petersen, Medpace Clinical Trial Manager discusses successful strategies and best practices for addressing some of these including: unique methods to site selection and feasibility, successful recruitment/retention approaches, overview of common study execution needs, and optimal training and monitoring strategies.
The momentum and muscle behind "finding the right drug for the right patient at the right dose" has further escalated with President Barack Obama’s announcement of a $215 million dollar Precision Medicine Initiative. In this webinar, Dr. Frank Smith will explore advances in precision medicine and how it is affecting clinical research. As a pediatric hematologist/oncologist, he will use his extensive clinical and research background as a backdrop for the discussion.
In this webinar, Medpace discusses how patient-focused clinical trial design and collaborative approaches to site enrollment can accelerate clinical research. This presentation features a doctor from Cincinnati Children's Hospital Medical Center and a parent of a child with Duchenne muscular dystrophy.
A hands-on approach provides significant advantages that can shorten drug development timelines and reduce development risk.
CRO manages multiple, complex statistical analysis deliverables for a program of studies, CDISC compliant outputs, and data pooling for NDA submission to the FDA with minimal sponsor oversight.
Cytel brings its expertise in adaptive designs to the design and implementation of the industry’s most innovative clinical trials. These highly flexible trials raise peculiar challenges for enrollment, data collection and regulatory submission. Why not have the industry leaders in adaptive design working on your adaptive trials?